Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].

Nederlands tijdschrift voor geneeskunde - 27 Mar 2004

Hooiveld E A, van Kuilenburg A B, Haanen J B, Westermann A M

Abstract excerpt

Two female patients, aged 48 and 52 years, developed severe bone marrow suppression and (gastrointestinal) mucositis following administration of capecitabine. Analysis of the dihydropyrimidine dehydrogenase (DPD) activity in peripheral blood mononuclear cells revealed the presence of DPD deficiency. Both patients recovered in 3-4 weeks, and both had a (partial) remission of their tumours. Capecitabine is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Fluorouracil

Share to Leukocytes, Mononuclear

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Identifiers

PMID: 15083629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].PMID 15083629Read ↗

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].Semantic proximity Read ↗

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity Read ↗

[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].Semantic proximity Read ↗

Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.Semantic proximity Read ↗

Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.Semantic proximity Read ↗

DPYD (Dihydropyrimidine Dehydrogenase) Variant c.2194G>A (Normal Metabolizer) with Severe Toxicities in Patients Treated with Fluoropyrimidine Based Regimens. A first Case Report from Bihar, IndiaSemantic proximity Read ↗

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.Semantic proximity Read ↗

Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.Semantic proximity Read ↗

[Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].Semantic proximity Read ↗

Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.Semantic proximity Read ↗

[Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.